左心室辅助装置患者长期管理的药物治疗考量
本文综述了左心室辅助装置(LVAD)患者长期管理中的药物治疗要点。LVAD 显著改变患者生理状态,带来独特并发症和用药考量;无禁忌时需抗栓治疗,优选华法林且 INR 目标随装置调整,基线通常 2-3。感染时需培养并覆盖可能病原体,慢性抗菌抑制可能必要;血压监测优选多普勒探头,目标平均动脉压 ≤80 mm Hg。
要点
- 无禁忌时 LVAD 患者需抗栓治疗,优选华法林,INR 基线目标通常 2-3。
- 怀疑感染时应获取培养,覆盖可能病原体并考虑长期感染耐药性。
- 血压监测优选多普勒探头,目标平均动脉压 ≤80 mm Hg。
核心结论
- LVAD 长期管理涉及多方面药物治疗考量,熟悉装置结构、病理生理改变和药理因素有助于药师提供更好建议。
研究设计与样本
- 综述,回顾当前指南和研究,涉及 LVAD 患者药物治疗管理。
主要发现
- LVAD 显著影响患者生理,导致独特医学并发症和用药考量。
- 无禁忌时需抗栓治疗以预防血栓,华法林优选且 INR 目标随装置调整,基线通常 2-3,可因复发血栓或难治性出血调整。
- 怀疑感染时应获取培养,覆盖可能病原体并考虑长期感染耐药性,慢性抗菌抑制可能必要。
- 消除速率常数和分布容积可能改变,LVAD 植入可能改善血糖控制。
- 血压监测优选多普勒探头,目标平均动脉压 ≤80 mm Hg。
关键数值与推荐
- 华法林 INR 基线目标通常 2-3,可根据复发血栓或难治性出血调整。
- 血压目标平均动脉压 ≤80 mm Hg,监测优选多普勒探头。
临床怎么用
- 药师应了解 LVAD 结构、植入后病理生理改变和药理考量,以向跨学科团队提供用药建议。
局限性
- 部分并发症的最佳治疗方案仍不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current guidelines and research pertaining to pharmacotherapy considerations for management of patients with left ventricular assist devices (LVADs) are reviewed. SUMMARY: LVADs are being used more frequently to sustain patients with end-stage heart failure who are on a waitlist or ineligible for heart transplantation. The devices significantly impact patient physiology leading to unique medical complications and pharmacotherapy considerations. Pharmacists can play a vital role in understanding and relaying relevant medication concerns to the interdisciplinary healthcare team. Although optimal treatment regimens for some complications are still unclear, evolving research provides key information to incorporate into decisions. The introduction of an LVAD requires antithrombotic therapy in the absence of contraindications to prevent thrombosis. Warfarin with a device-dependent International Normalized Ratio (INR) goal is preferred. The baseline INR goal is usually 2-3 but can be adjusted for recurrent thrombosis or refractory bleeding. When infection is suspected, cultures should be obtained, covering likely pathogens with consideration of resistance in long-standing infections. Chronic antimicrobial suppression may be warranted. Elimination rate constant and volume of distribution may be altered. LVAD implantation may improve glycemic control. Doppler probe is preferred to monitor blood pressure, with a goal mean arterial pressure of ≤80 mm Hg. CONCLUSION: Many pharmacotherapy considerations are necessary for the long-term management of patients with an LVAD. Awareness of LVAD structure, pathophysiologic alterations after LVAD implantation, and pharmacologic considerations will help pharmacists provide better recommendations.
引用
- Nicholson JD, Kaakeh Y. Pharmacotherapy considerations for long-term management of patients with left ventricular assist devices. Am J Health Syst Pharm. 2018. PMID: 29802111. doi:10.2146/ajhp170317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。